Search research articles
Contact Us
Filters
Showing results (151-160 of 418) with videos related to
Page
of 42
Sort By:
Clinical Chemistry
|
December 9, 2023
MAESTRO-Pool Enables Highly Parallel and Specific Mutation-Enrichment Sequencing for Minimal Residual Disease Detection in Cohort Studies
Timothy Blewett, Justin Rhoades, Ruolin Liu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 17, 2006
Expression of tumor necrosis factor--related apoptosis-inducing ligand receptors 1 and 2 in melanoma
Mary M McCarthy, Kyle A DiVito, Mario Sznol, et al.
Plos One
|
August 13, 2013
Expression of drug targets in patients treated with sorafenib, carboplatin and paclitaxel
Lucia B Jilaveanu, Fengmin Zhao, Christopher R Zito, et al.
Pigment Cell & Melanoma Research
|
August 20, 2010
Meeting report from the Third Global Workshop on Melanoma
Sanjiv S Agarwala, Alessandra di Pietro, Keith T Flaherty, et al.
The Oncologist
|
May 7, 2017
Impact of Age on Outcomes with Immunotherapy for Patients with Melanoma
Allison S Betof, Ryan D Nipp, Anita Giobbie-Hurder, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 29, 2012
Marked, homogeneous, and early [18F]fluorodeoxyglucose-positron emission tomography responses to vemurafenib in BRAF-mutant advanced melanoma
Grant A McArthur, Igor Puzanov, Ravi Amaravadi, et al.
The New England Journal of Medicine
|
September 8, 2010
Inhibition of mutated, activated BRAF in metastatic melanoma
Keith T Flaherty, Igor Puzanov, Kevin B Kim, et al.
British Journal of Cancer
|
August 17, 2019
Impact of depth of response on survival in patients treated with cobimetinib ± vemurafenib: pooled analysis of BRIM-2, BRIM-3, BRIM-7 and coBRIM
Karl D Lewis, James Larkin, Antoni Ribas, et al.
Nature
|
April 24, 2025
Editorial Expression of Concern: A melanocyte lineage program confers resistance to MAP kinase pathway inhibition
Cory M Johannessen, Laura A Johnson, Federica Piccioni, et al.
Nature
|
November 5, 2013
A melanocyte lineage program confers resistance to MAP kinase pathway inhibition
Cory M Johannessen, Laura A Johnson, Federica Piccioni, et al.
Page
of 42
Search research articles
Search
Showing results (151-160 of 418) with videos related to
Sort By:
Page
of 42
Clinical Chemistry
|
December 9, 2023
MAESTRO-Pool Enables Highly Parallel and Specific Mutation-Enrichment Sequencing for Minimal Residual Disease Detection in Cohort Studies
Timothy Blewett, Justin Rhoades, Ruolin Liu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 17, 2006
Expression of tumor necrosis factor--related apoptosis-inducing ligand receptors 1 and 2 in melanoma
Mary M McCarthy, Kyle A DiVito, Mario Sznol, et al.
Plos One
|
August 13, 2013
Expression of drug targets in patients treated with sorafenib, carboplatin and paclitaxel
Lucia B Jilaveanu, Fengmin Zhao, Christopher R Zito, et al.
Pigment Cell & Melanoma Research
|
August 20, 2010
Meeting report from the Third Global Workshop on Melanoma
Sanjiv S Agarwala, Alessandra di Pietro, Keith T Flaherty, et al.
The Oncologist
|
May 7, 2017
Impact of Age on Outcomes with Immunotherapy for Patients with Melanoma
Allison S Betof, Ryan D Nipp, Anita Giobbie-Hurder, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 29, 2012
Marked, homogeneous, and early [18F]fluorodeoxyglucose-positron emission tomography responses to vemurafenib in BRAF-mutant advanced melanoma
Grant A McArthur, Igor Puzanov, Ravi Amaravadi, et al.
The New England Journal of Medicine
|
September 8, 2010
Inhibition of mutated, activated BRAF in metastatic melanoma
Keith T Flaherty, Igor Puzanov, Kevin B Kim, et al.
British Journal of Cancer
|
August 17, 2019
Impact of depth of response on survival in patients treated with cobimetinib ± vemurafenib: pooled analysis of BRIM-2, BRIM-3, BRIM-7 and coBRIM
Karl D Lewis, James Larkin, Antoni Ribas, et al.
Nature
|
April 24, 2025
Editorial Expression of Concern: A melanocyte lineage program confers resistance to MAP kinase pathway inhibition
Cory M Johannessen, Laura A Johnson, Federica Piccioni, et al.
Nature
|
November 5, 2013
A melanocyte lineage program confers resistance to MAP kinase pathway inhibition
Cory M Johannessen, Laura A Johnson, Federica Piccioni, et al.
Page
of 42